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What makes an academic paper useful for
health policy?
Christopher J. M. Whitty
Abstract
Evidence-based policy ensures that the best interventions are effectively implemented. Integrating rigorous, relevant
science into policy is therefore essential. Barriers include the evidence not being there; lack of demand by policymakers;
academics not producing rigorous, relevant papers within the timeframe of the policy cycle. This piece addresses the last
problem. Academics underestimate the speed of the policy process, and publish excellent papers after a policy decision
rather than good ones before it. To be useful in policy, papers must be at least as rigorous about reporting their
methods as for other academic uses. Papers which are as simple as possible (but no simpler) are most likely to be
taken up in policy. Most policy questions have many scientific questions, from different disciplines, within them.
The accurate synthesis of existing information is the most important single offering by academics to the policy
process. Since policymakers are making economic decisions, economic analysis is central, as are the qualitative social
sciences. Models should, wherever possible, allow policymakers to vary assumptions. Objective, rigorous, original studies
from multiple disciplines relevant to a policy question need to be synthesized before being incorporated into policy.
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Introduction
Health and science policy can mean many things, but in
this paper, it is the decisions taken by regional, national
or multilateral organisations that aim to have an impact
on health, both international and domestic. These may
be decisions on resource allocation, legislation or prac-
tice guidelines. Policy decisions are invariably weakened
when they do not take account of the best current
knowledge. Incorporating relevant research findings into
policy and practice should therefore be central to the
aims of those undertaking practically oriented health re-
search, including in the basic and social sciences. There
are a number of reasons policy decisions are not more
evidence-based but three predominate. The first is
simply that the research has not been conducted; for
many important policy decisions it is impossible to be
evidence-based because the evidence is currently not
there. This is the responsibility and skill-set of academia,
although policy-makers can help prioritize key questions.
The second is a demand-side problem, with policymakers
unwilling or unable to take account of good existing evi-
dence. Those of us in the academic community often
blame this demand-side weakness, but at least as much of
a barrier is a supply-side problem; the academic commu-
nity is often weak in producing papers usable in policy
even when the evidence is there.
It is this third problem that this discussion piece sets
out to explore: how can academics write papers that are
more likely to be useful within policy? It should be the
easiest to fix if, as academics and scientists, we are
serious about trying to improve policy. I was asked to
write it having just stopped being Chief Scientific Adviser
at the UK Department for International Development
(DFID). This role was an interface between science and
policy, and I briefly also acted as director of policy. It is
therefore one person’s view rather than a consensus state-
ment, with a bias to international development, but the
points made are likely to be common ground to most
policymakers trying to get policy based on the best
available science. What makes a good scientific policy
paper, defined as a paper likely to influence and improve
policy decisions based on science?
Discussion
The starting point for any piece of communication, and
a scientific paper is a form of communication, is: who is
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the audience? In one sense, anybody who makes decisions
is a policymaker. A guideline writing group or a hospital
management committee are. Policymakers discussed in
this paper, however, are those having to operate at a
larger, generally national or multinational scale. Whilst
there are many variations on this, there are some com-
mon features which are often forgotten by those who
think they are writing for policymakers.
The first is the relatively limited range of things policy-
makers can do. They can exhort; in some cases they can
legislate; most commonly they deploy resources but this
means moving resources from one priority to another
rather than creating new resource. The second follows
from the fact that their main lever is moving constrained
resources around and choosing between different ratios
of financial allocation; they tend to think like economists
or be advised by them, and economics is the training for
many policymakers, whether civil servants or politicians.
This does not mean good economic analysis is essential
to influence policy (although it certainly helps), but good
policymakers will always be asking the question ‘what is
the opportunity cost of this new initiative?’. Policymakers
also therefore can be more numerate than scientists often
give them credit for, and have access to well trained
statisticians.
Three other elements of the policy-making environment
need to be borne in mind. Policy-making is generally ex-
tremely fast by academic standards. Many quite complex
policy decisions are taken in days, weeks or at most a few
months, the time it takes a competent PhD student to
begin an introductory chapter. This leaves almost no time
for pulling complex evidence together once the policy
process is underway, which therefore has to be done in
advance. The second is that policies fall on a continuum
between purely political decisions, and purely technical
decisions. A political decision might, for example, be
whether to allocate resources to primary schools or stroke
care; science has little to offer in this choice. A purely
technical decision is which drug to use for thrombolysis in
stroke in which political considerations should usually
play no part. Most difficult policy problems lie between
these two extremes. Policymakers are assailed on all sides
by people with strong opinions pushing their point of
view. The evidence-light (or evidence-free) opinions of
distinguished scientists are of no more use than any other
advocacy group. If scientists take a biased approach to the
evidence they quote, or use positional power to give their
personal opinion extra weight, they are positively damaging
to rational policy-making and may well harm vulnerable
people by persuading policymakers to be irrational in the
allocation of resources in a way that leads to net loss.
Finally, it is rare that all the evidence needed for a
moderately complex policy problem comes from a single
discipline, and rarer still that it comes from a single
study. As an example, if you consider a seemingly rela-
tively simple question like how best to target antimalarial
drugs in Africa, a serious answer will need contributions
from several basic sciences, epidemiology, clinical trials,
anthropology and economics, and the answer may vary by
cultural and epidemiological setting. Despite the multidis-
ciplinary nature of the decision-making process, papers
that address only one aspect rigorously are still extremely
useful for policy. Improving the evidence base and redu-
cing uncertainty for every link in the assumed chain of
causality between a policy decision and its intended out-
come is valuable. It does, however, mean that leaping from
a single aspect of a problem (most scientific studies) to
the proposed solution should be done with due caution,
and a degree of humility.
Principles of what makes a good policy paper
(and what does not)
If you compare papers used by policymakers that are
genuinely useful for improving the evidence base for
policy making with those that are often published as a
‘policy paper’ or in the policy section of journals, the
mismatch is often considerable. Many of these ‘policy
papers’ are simply footnoted opinion pieces, or even
naked advocacy. Others start from the policy decision
individual scientists think should be taken rather than
from the evidence around the problem that needs to be
solved, and suffer from all the problems which occur
when intelligent people start with a solution and try and
fit the problem to it. Others offer policy advice which
would work fine if we consider only the science relevant
to their discipline and ignore all the inconvenient com-
plexities brought in by other relevant sciences, including
the social sciences. This is not a new problem, but what
Sir Francis Bacon, an early scientist-policymaker called
the ‘idols of the cave’, the tendency to give disproportionate
weight to your own intellectual tradition [1]. Finally, some
scientists appear to believe that a paper for policymakers,
which might affect vulnerable lives, requires less intellec-
tual and methodological rigour than one aimed at their
academic peers; this is incorrect.
Fortunately, there are a wide range of types of paper
which have considerable use to inform policy and which
can be very influential. They have some things in common.
1) They state explicitly the policy problem or
aspect of a policy problem the paper addresses.
This makes them easy to identify. A policy problem
is not usually the same as a scientific problem, and
may have several scientific problems incorporated
within it.
2) They are explicit about methodologies, limitations
and weaknesses. This may sound obvious to writers
from some scientific traditions but, for example, in
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many social sciences, very limited methods may be
outlined in reputable journals [2]. The technical part
of any policy team should be trying to assess the
strength of each bit of evidence used, whether via
formal grading system as used in medical guidelines
or more informally [3]. Doing this without
methodologies laid out is nearly impossible.
3) The authors have made a serious attempt to
minimise their own biases in both methodology
and interpretation. Scientists can be advocates, or
they can provide the best possible balanced
assessment of the evidence but they cannot do both
simultaneously. It has to be clear to policymakers
which horse they are riding. Papers seen as advocacy
are likely to be discounted.
4) Since the policy process tends to be very fast, papers
must be timely. An 80 % right paper before a policy
decision is made it is worth ten 95 % right papers
afterwards, provided the methodological limitations
imposed by doing it fast are made clear. The use
of fast-tracking by journals seems more logical for
papers because they are time-limited in their
impact than because they are deemed important.
5) Remembering that the audience may be intelligent
laypeople authors should apply the aphorism
attributed to Einstein; be as simple as possible
(but no simpler) in methods and language. Authors,
referees and editors can transform papers making a
simple point using methods easily understood by
policymakers into Baroque complexity understood
only by modelers or statisticians by insisting on
using techniques irrelevant to the key policy message
which only add a spurious level of precision. Some
papers (especially but not exclusively in the social
science journals) use unnecessarily complex language
or redundant jargon. Sensible policymakers prefer a
paper they understand, including its flaws, to one
they do not, however sophisticated and apparently
precise it looks. It is possible to be simple whilst
being rigorous.
6) Describing the problem that needs resolving is
only useful until the description is clear, and
policymakers understand there needs to be action.
Then the policy question needs to be asked: what is
the evidence about the available options for things
we can do to resolve the problem? This should be
obvious, but it is surprising how many scientists
continue to describe a problem in greater and
greater detail for years after policymakers have
clocked it, without going the next step of designing
and testing interventions.
7) Don’t feel the need to spell out policy implications.
This may sound counter-intuitive, but many good
scientific papers are let down by simplistic, grandiose
or silly policy implications sections. Policymaking
is a professional skill; most scientists have no
experience of it and it shows. In DFID, we stopped
asking people undertaking commissioned systematic
reviews to write a ‘policy implications’ summary of
their review. This was because the understanding
of the real policy questions were usually poor even
when the review was itself very well done and
therefore undermined the paper. Worse, trying to
work up to a policy position can unconsciously
bias scientists towards trying to get a neat policy
narrative from a complex picture, or downplay
inconvenient facts. Therefore, in general, the data
collection and analysis process and the policy
process are best kept separate. If you feel it is useful
to give your policy analysis based on your data be
modest: few papers underestimate their policy
importance, many substantially overestimate it and
many do not provide the social context.
Types of paper most commonly useful in policy
Synthesis
Way ahead of any other academic contribution to
policy-making is rigorous and unbiased synthesis of
current knowledge. It is an unfortunate side-effect of the
incentives built into academic life, including the UK
Research Excellence Framework (REF), that there is a
tendency to try and claim an individual study as the
basis for a policy decision. In reality, policy should
always be based on the whole sweep of current scientific
knowledge, usually from multiple disciplines. Some
scientists seem to assume a two-stage process where the
individual research is conducted, and then policies made
on the basis of that. The reality should be a three-stage
process: that original research is conducted, then re-
search from multiple instances and disciplines is synthe-
sised, and then policies made on the basis of all the
available synthesized evidence. Unfortunately, despite
accurate synthesis being by far the most useful academic
skill for policy-making, it tends to have low prestige in
the academic community, a form of snobbery which is
very unhelpful if we believe our own rhetoric that
science can and should change the world.
Health-related sciences have contributed a major tool
for synthesis which is systematic reviews. These are now
being increasingly used in other disciplines for policy
[4]. The general principles of systematic reviews of a
trawl for evidence relevant to the policy question to
avoid positive publication bias, followed by a quality
filter are widely applicable. Systematic reviews in the
narrower and sometimes theological definition of Cochrane
or Campbell reviews often discard anything which is not a
randomised trial. Unfortunately, this means that a large
proportion of the papers most relevant to policy, but which
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do not have experimental quantitative data, despite being
in their own way rigorous, are also discarded. Systematic
reviews are therefore often necessary, but certainly not suf-
ficient. Many important policy questions (as opposed to
clinical questions) are not amenable to trials. It should be
acknowledged also that many papers labeled as systematic
reviews are methodologically weak or poorly conceived; a
bad systematic review should have no place in the GRADE
system, but there are a lot out there. In particular there is a
tendency to jump from the systematic review to an in-
appropriate meta-analysis. If the academic community as a
whole could do one thing to improve the pathway from
research to policy, it would be to improve the status, quality
and availability of good synthesis. For example some
current initiatives by the UK Economic and Social Research
Council (ESRC) into new methods for synthesizing social
science are an encouraging development [5].
Papers which challenge current thinking with data
Most well-trained policymakers find papers which chal-
lenge or modify their assumptions extremely useful. It is
far better (and less embarrassing) to get a challenge be-
fore a decision is made, than to realise you have misun-
derstood it afterwards. A challenge, clarification or gloss
on current thinking has weight if it is based on solid
data neutrally presented, but not when based only on
opinion. A data-based paper which makes a single policy
point well backed up and with all the limitations laid out
is frequently extremely influential in policy decisions.
The more points that are loaded onto a paper the less
easy it is for the policy process to digest it so making
one point well backed by rigorous analysis will generally
have greater impact than a complex analysis of multiple
policy points.
Models and economic models
Models are frequently used to predict the possible im-
pacts of a change in policy, or its cost-benefit implica-
tions. Models unfortunately tend to induce extreme
reactions in most people, including policymakers, who
are not modelers. Either they tend to believe them com-
pletely, or ignore them completely. Clearly the right
place is between the two. The tendency of some modelers
to present them as scientific predictions of the future
rather than models does not help. Models are widely used
in government, and some models arguably have too much
influence. They are generally most useful when they iden-
tify impacts of policy decisions which are not predictable
by commonsense; the key is usually not that they are
‘right’, but that they provide an unpredicted insight. A
good recent example was the model which predicted the
upswing of Ebola in West Africa and helped spur (belated)
international action [6]. The model was not ‘right’ in that
it did not predict accurately which countries would be
most heavily affected, but it conveyed very clearly the
implications of an epidemic which would compound up
over time.
Authors of modelling papers can do things to make
their work substantially more useful for policy. The best
is to provide an interactive interface, where if the policy-
maker does not agree with the starting assumptions of
the model, they can change them. This is particularly
important for the key variables, but also anything which
has a big impact on the model outcomes in sensitivity
analysis. A nice example from outside the health field is
this model for making carbon reduction decisions, which
was written by a combined science and policy team [7].
This should be very easy to do for any model. One of
the major weaknesses of many models is that they make
assumptions based on expert opinion where there are no
reliable data, and expert opinion can vary widely [8].
Providing the reader with the opportunity to put in their
own assumptions makes intellectual as well as communi-
cation sense. Keeping the model simple is also important.
There is likely to be an inverse relationship between the
complexity of the model (making its workings incompre-
hensible to most readers) and its uptake by policymakers
who have a reasonable understanding of modeling but do
not trust black box models.
Economic models, in particular from microeconomics
(of which most health economics is a subset) are in a
different category because so many policymakers are
trained in economics. They generally have fewer prob-
lem in understanding economic models including their
strengths and weaknesses.
Papers from the social sciences
The great majority of policy initiatives, including health,
involve some behavioral aspects, and most involve be-
havior change. Many policy decisions do not turn out
the way they were intended because people do not be-
have in the way policymakers and scientists thought they
would, or should. There is a wide open goal for timely,
relevant, rigorous and readable qualitative and quantita-
tive social science addressing practical questions in policy-
making. The supply of such research is thin compared to
the demand, and methods for synthesizing it in a rigorous
way are not as well developed or universally agreed as in
clinical medicine [9]. A surprising number of people who
conduct trials do not, alongside of this, conduct the social
science research which would provide the context to make
them translatable into policy. A lot of excellent (in the
sense it is academically well done) social research is
conducted, but the amount that is usable for policy is a
fraction of this. Some ostensibly policy-relevant social
research is methodologically weak. As an academic com-
munity, we need to address this seriously; with the excep-
tion of economics the social sciences punch well below
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their weight in policy, and in my experience this is more a
supply-side than a demand-side problem.
Trials
Few methodologies are clearer, and easier to communi-
cate, than a trial. Like clinicians, policymakers generally
like them because they give a quantitative dichotomous
answer (it worked or it did not, and by how much) to a
question about which intervention works best. A good
trial is difficult to argue with, and even a methodologically
weak trial can get a lot of traction. They are relatively easy
to turn into an economic analysis on cost-benefit or cost-
effectiveness, although despite this being a key policy con-
sideration, surprisingly few triallists do this except as an
afterthought. Not all policy questions suit a trial design,
but many do. From a policy perspective, the main problem
with many trials is that they are a form of efficacy trial
(ideal world) rather than effectiveness or pragmatic trial
(what would happen under realistic circumstances).
Anybody who understands trials knows that there is
often a major gap between efficacy and effectiveness
[10]. Making policy on the basis of efficacy trials may
be better than nothing, but it would be much better also
to have a (costed) effectiveness trial, and preferably more
than one backed up by economic and social analysis.
Conclusions
Getting relevant science and research into policy is
essential. There are several barriers, but the easiest to re-
duce is making papers more relevant and accessible to
policymakers. Opinion pieces backed up by footnotes
are generally unusable for policy. Objective, rigorous,
simply written original papers from multiple disciplines
with data can be very helpful. These then need to be well
synthesized.
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